When to Look for Von Hippel-Lindau Disease in Gastroenteropancreatic Neuroendocrine Tumors?Ling H. · Cybulla M. · Schaefer O. · Arnold C. · Schories M. · Neumann H.P.H.
Departments of aNephrology and Hypertension, bRadiology, and cGastroenterology and Endocrinology, Albert-Ludwigs-Universität, Freiburg, Germany
Von Hippel-Lindau (VHL) disease is a progressive autosomal dominant multisystem disorder that is associated with a germ line mutation of the VHL gene on the short arm of chromosome 3. A variety of benign and malignant diseases, including eye and CNS hemangioblastomas, renal cell carcinoma and pheochromocytoma are the major components. Gastroenteropancreatic neuroendocrine tumors are also listed among the typical complications, although these occur seldom. Virtually all such tumors are pancreatic islet cell tumors. VHL-associated islet cell tumors are mostly hormone-inactive. They can be detected during screening investigations according to the multidisciplinary disorder or by workup of space-occupying lesions. There are no specific predictors for malignancy in VHL-associated islet cell neoplasias, but tumors smaller than 3 cm in diameter are believed to be always benign. Gadolinium-enhanced MRI is currently the imaging method of choice, but contrast-enhanced CT is also a diagnostic option. The spectrum of manifestations is illustrated by selected cases.
Hartmut P.H. Neumann
Hugstetter Strasse 55
DE–79106 Freiburg (Germany)
Tel. +49 761 270 3363, Fax +49 761 270 3778, E-Mail email@example.com
Number of Print Pages : 8
Number of Figures : 10, Number of Tables : 2, Number of References : 42
Neuroendocrinology (International Journal for Basic and Clinical Studies on Neuroendocrine Relationships)
Vol. 80, No. Suppl. 1, Year 2004 (Cover Date: Released October 2004)
Journal Editor: C. Kordon, Paris
ISSN: 0028–3835 (print), 1423–0194 (Online)
For additional information: http://www.karger.com/nen